Treatment of bipolar depression

CNS Spectrums

Volumn 18, Issue 4, 2013, Pages 177-187

  Musetti, Laura ^a   Del Grande, Claudia ^a   Marazziti, Donatella ^a   Dell'Osso, Liliana ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Antidepressants; atypical antipsychotics; bipolar depression; bipolar spectrum; depressive mixed state; mood stabilizers; nonpharmacological treatment; pharmacological treatment

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CARBAMAZEPINE; DOCOSAHEXAENOIC ACID; ESCITALOPRAM; FLUOXETINE; ICOSAPENTAENOIC ACID; INOSITOL; KETAMINE; LAMOTRIGINE; LITHIUM SALT; MEMANTINE; MODAFINIL; MOOD STABILIZER; OLANZAPINE; PAROXETINE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROATE SEMISODIUM; VENLAFAXINE; ZIPRASIDONE;

ANTIDEPRESSANT ACTIVITY; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CHEMOPROPHYLAXIS; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ELECTROCONVULSIVE THERAPY; EXPERIMENTAL THERAPY; FAMILY THERAPY; HUMAN; HYPOMANIA; LONG TERM CARE; MONOTHERAPY; OFF LABEL DRUG USE; PRIORITY JOURNAL; PSYCHOEDUCATION; PSYCHOTHERAPY; REVIEW; THERAPY EFFECT;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; ELECTROCONVULSIVE THERAPY; HUMANS; PROGNOSIS; PSYCHOTHERAPY; TREATMENT OUTCOME;

EID: 84880526093     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852912001009     Document Type: Review

References (111)

1. Judd LL, Akiskal HS, Schettler PJ, et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry. 2005; 62(12): 1322-1330.
2. Bauer M, Ritter P, Grunze H, Pfenning A. Treatment options for acute depression in bipolar disorder. Bipolar Disord. 2012; 14(suppl 2): 37-50.
3. Amit BH, Weizman A. Antidepressant treatment for acute bipolar depression: an update. Depress Res Treat. 2012; 2012: 684725.
4. Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry. 2003; 64(6): 680-690.
5. Judd LL, Schettler PJ, Akiskal HS, et al. Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/ recurrence. Arch Gen Psychiatry. 2008; 65(4): 386-394.
6. Angst J, Angst F, Gerber-Werder R, Gamma A. Suicide in 406 mod-disorder patients with and without long-term medication: a 40 to 44 years' follow-up. Arch Suicide Res. 2005; 9(3): 279-300.
7. Young AH, Nemeroff CB. Pharmacological treatment of bipolar depression. In: Yatham LN, Maj M, eds. Bipolar Disorder: Clinical and Neurobiological Foundations. Chichester, UK: John Wiley & Sons, Ltd; 2010: 294-303.
8. Vieta E, Colom F, Corbella B, et al. Clinical correlates of psychiatric comorbidity in bipolar I patients. Bipolar Disord. 2001; 3(5): 253-258.
9. Hirschfeld RMA, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? Results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry. 2003; 64(2): 161-174.
10. Goodwin FK, Jamison KR. Manic-Depressive Illness, 2nd ed. New York: Oxford University Press; 2007.
11. Baldessarini RJ, Vieta E, Calabrese JR, et al. Bipolar depression: overview and commentary. Harv Rev Psychiatry. 2010; 18(3): 143-157.
12. Cassano GB, Akiskal HS, Savino M, et al. Proposed subtypes of bipolar II disorder: with hypomanic episodes and/or with hyperthymic temperament. J Affect Disord. 1992; 26(2): 127-140.
13. Akiskal HS, Maser JD, Zeller PJ, et al. Switching from ''unipolar'' to bipolar II: an 11-year prospective study of clinical and temperamental predictors in 559 patients. Arch Gen Psychiatry. 1995; 52(2): 114-123.
14. Perlis RH, Brown E, Baker RW, Nirenberg AA. Clinical features of bipolar depression vs. major depressive disorder in large multicenter trials. Am J Psychiatry. 2006; 163(2): 225-231.
15. Thase ME. Recognition and diagnosis of atypical depression. J Clin Psychiatry. 2007; 68(suppl 8): 11-16.
16. Merikangas KR, Herrell R, Swendsen J, et al. Specificity of bipolar spectrum conditions in the comorbidity of mood and substance use disorders: results from the Zurich cohort study. Arch Gen Psychiatry. 2008; 65(1): 47-52.
17. El-Mallakh RS, Ghaemi SN, Sagduyu K, et al. STEP-BD Investigators. Antidepressant-associated chronic irritable dysphoria (ACID) in STEP-BD patients. J Affect Disord. 2008; 111(2-3): 372-377.
18. Frye MA, Helleman G, McElroy SL, et al. Correlates of treatment-emergent mania associated with antidepressant treatment in bipolar depression. Am J Psychiatry. 2009; 166(2): 164-172.
19. Rybakowski JK. Bipolarity and inadequate response to antidepressant drugs: clinical and psychopharmacological perspective. J Affect Disord. 2012; 136(1-2): e13-19.
20. Constant A, Castera L, Dantzer R, et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry. 2005; 66(8): 1050-1057.
21. Hardoy MC, Cadeddu M, Serra A, et al. A pattern of cerebral perfusion anomalies between major depressive disorder and Hashimoto thyroiditis. BMC Psychiatry. 2011; 11: 148-154.
22. Cassano GB, Dell'Osso L, Frank E, et al. The bipolar spectrum: a clinical reality in search of diagnostic criteria and an assessment methodology. J Affect Disord. 1999; 54(3): 319-328.
23. Akiskal HS, Pinto O. The soft bipolar spectrum: footnotes to Kraepelin on the interface of hypomania, temperament and depression. In: Marneros A, Angst J, eds. Bipolar Disorders: 100 Years After Manic-Depressive Insanity. Dordrecht, Netherlands: Kluwer Academic Publishers; 2000: 37-62.
24. Dell'Osso L, Armani A, Rucci P, et al. Measuring mood spectrum: comparison of interview (SCI-MOODS) and self-report (MOODS-SR) instruments. Compr Psychiatry. 2002; 43(1): 69-73.
25. Goldberg JF, Perlis RH, Bowden CL, et al. Manic symptoms during depressive episodes in 1,380 patients with bipolar disorder: findings from the STEP-BD. Am J Psychiatry. 2009; 166(2): 173-181.
26. Goldberg JF, Perlis RH, Ghaemi SN, et al. Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BD. Am J Psychiatry. 2007; 164(9): 1348-1355.
27. Kasper S, Calabrese JR, Johnson G, et al. International Consensus Group on the evidence-based pharmacological treatment of bipolar I and II depression. J Clin Psychiatry. 2008; 69(10): 1632-1646.
28. Goodwin GM. Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition'recommendations from the British Association for Psychopharmacology Journal of Psychopharmacology. J Psychopharmacol. 2009; 23(4): 346-388.
29. National Institute for Health and Clinical Excellence. Bipolar disorder. The management of bipolar disorder in adults, children and adolescents, in primary and secondary care. NICE Clinical Guideline 38, update 2009. http://guidance.nice.org.uk/CG38
30. Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009; 11(3): 225-255.
31. Grunze H, Vieta E, Goodwin GM, et al. WFSBP task Force on treatment guidelines for bipolar disorders. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010; 11(2): 81-109.
32. Nivoli AM, Colom F, Murru A, et al. New treatment guidelines for acute bipolar depression: a systematic review. J Affect Disord. 2011; 129(1-3): 14-26.
33. Geddes JR, Burgess S, Hawton K, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004; 161(2): 217-222.
34. Young AH, McElroy SL, Bauer M, et al. EMBOLDEN I (Trial 001) Investigators. A double-blind, placebocontrolled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry. 2010; 71(2): 150-162.
35. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry. 2005; 162(10): 1805-1819.
36. Baldessarini RJ, Tondo L, Davis P, et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disord. 2006; 8(5 pt 2): 625-639.
37. Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry. 2011; 72(3): 356-366.
38. Bowden CL, Singh V. Lamotrigine (Lamictal IR) for the treatment of bipolar disorder. Expert Opin Pharmacother. 2012; 13(17): 2565-2571.
39. Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord. 2008; 10(2): 323-333.
40. Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry. 2009; 194(1): 4-9.
41. Calabrese JR, Bowden CL, Sachs GS, et al. Double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry. 1999; 60(2): 79-88.
42. van der Loos ML, Mulder PG, Hartong EG, et al. Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(2): 223-231.
43. Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry. 2006; 163(2): 210-216.
44. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder: Lamictal 614 Study Group. J Clin Psychiatry. 2000; 61(11): 841-850.
45. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry. 2004; 65(3): 432-441.
46. Saunders KEA, Goodwin GM. New approaches in the treatment of bipolar depression. Curr Top Behav Neurosci. In press. DOI: 10.1007/7854-2012-209.
47. Smith LA, Cornelius VR, Azorin JM, et al. Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis. J Affect Disord. 2010; 122(1-2): 1-9.
48. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry. 2000; 57(5): 481-489.
49. Geddes JR, Goodwin GM, Rendell J, et al. E. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010; 375(9712): 385-395.
50. Greil W, Kleindienst N, Erazo N, Mu' ller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol. 1998; 18(6): 455-460.
51. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006; 26(6): 600-609.
52. Weisler RH, Calabrese JR, Thase ME, et al. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post-hoc analysis of combined results from two double-blind, randomized, placebo-controlled studies. J Clin Psychiatry. 2008; 69(5): 769-782.
53. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Trial 127 Investigators. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (Trial 127). Am J Psychiatry. 2009; 166(4): 476-488.
54. McElroy SL, Weisler RH, Chang W, et al. EMBOLDEN II (Trial D1447C00134) Investigators. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry. 2010; 71(2): 163-174.
55. Vieta E, Suppes T, Eggens I, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. 2008; 109(3): 251-263.
56. Hardoy MC, Garofalo A, Carpiniello B, et al. Combination quetiapine therapy in the long-term treatment of patients with bipolar I disorder. Clin Pract Epidemiol Ment Health. 2005; 18: 1-7.
57. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003; 60(11): 1079-1088.
58. Brown EB, Mcelroy SL, Keck PE Jr, et al. A 7 week, randomized, double-blind trial of olanzapine/ fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 2006; 67(7): 1025-1033.
59. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006; 163(2): 247-256.
60. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003; 160(7): 1263-1271.
61. Tohen M, GreilW, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005; 162(7): 1281-1290.
62. Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol. 2008; 28(1): 13-20.
63. Marcus RN, McQuade RD, Carson WH, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2008; 28(2): 156-165.
64. Keck Jr PE, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry. 2007; 68(10): 1480-1491.
65. Yerevanian BI. The role of antidepressants in bipolar disorder. In: Akiskal HS, Tohen M, eds. Bipolar Psychopharmacotherapy: Caring for the Patient, 2nd ed. New York: John Wiley & Sons, Ltd.; 2011: 299-316.
66. Baldessarini RJ, Leahy L, Arcona S, et al. Patterns of psychotropic drug prescription for U.S. patients with diagnoses of bipolar disorders. Psychiatr Serv. 2007; 58(1): 85-91.
67. Carta MG, Aguglia E, Balestrieri M, et al. The lifetime prevalence of bipolar disorders and the use of antidepressant drugs in bipolar depression in Italy. J Affect Disord. 2012; 136(3): 775-780.
68. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007; 356(17): 1711-1722.
69. Ghaemi SN, Wingo AP, Filkowski MA, et al. Effectiveness of long-term antidepressant treatment in bipolar disorder: meta-analysis of benefits and risks. Acta Psychiatr Scand. 2008; 118(5): 347-356.
70. Grunze HC. Switching, induction of rapid cycling, and increased suicidality with antidepressants in bipolar patients: fact or overinterpretation? CNS Spectr. 2008; 13(9): 790-795.
71. Licht RW, Gijsman H, Nolen WA, Angst J. Are antidepressants safe in the treatment of bipolar depression? A critical evaluation of their potential risk to induce switch into mania or cycle acceleration. Acta Psychiatr Scand. 2008; 118(5): 337-346.
72. Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression'lack of manic induction. J Affect Disord. 2005; 87(1): 121-130.
73. Altshuler LL, Suppes T, Black DO, et al. Lower switch rate in depressed patients with bipolar II than bipolar I disorder treated adjunctively with second-generation antidepressants. Am J Psychiatry. 2006; 163(2): 313-315.
74. Amsterdam JD, Shults J. Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode. J Clin Psychopharmacol. 2010; 30(3): 306-311.
75. Parker G, Tully L, Olley A, Hadzi-Pavlovic D. SSRIs as mood stabilizers for bipolar II disorder? a proof of concept study. J Affect Disord. 2006; 92(2-3): 205-214.
76. Amsterdam JD, Shults J. Comparison of short-term venlafaxine versus lithium monotherapy for bipolar II major depressive episode: a randomized open-label study. J Clin Psychopharmacol. 2008; 28(2): 171-181.
77. Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004; 161(9): 1537-1547.
78. Sidor MM, MacQueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry. 2011; 72(2): 156-167.
79. Tondo L, Baldessarini RJ, Va'zquez G, et al. Clinical responses to antidepressants among 1036 acutely depressed patients with bipolar or unipolar major affective disorders. Acta Psychiatr Scand In press. DOI: 10.1111/acps.12023.
80. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry. 2006; 189: 124-131.
81. Vieta E, Martinez-Ara'n A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry. 2002; 63(6): 508-512.
82. Tondo L, Va'zquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. Acta Psychiatr Scand. 2010; 121(6): 404-414.
83. Undurraga J, Baldessarini RJ, Valenti M, et al. Bipolar depression: clinical correlates of receiving antidepressants. J Affect Disord. 2012; 139(1): 89-93.
84. Joffe RT, MacQueen GM, Marriott M, Young LT. One-year outcome with antidepressants-treatment of bipolar depression. Acta Psychiatr Scand. 2005; 112(2): 105-109.
85. Altshuler LL, Post RM, Helleman G, et al. Impact of antidepressants continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study. J Clin Psychiatry. 2009; 70(4): 450-457.
86. Ghaemi SN, Ostacher MM, El-Mallakh RS, et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry. 2010; 71(4): 372-380.
87. Frye MA, Grunze H, Suppes T, et al. A placebocontrolled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry. 2007; 164(8): 1242-1249.
88. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatmentresistant bipolar depression. Am J Psychiatry. 2004; 161(3): 564-566.
89. Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry. 2004; 56(1): 54-60.
90. Diazgranados N, Ibrahim L, Brutsche NE, et al. A randomized add-on trial of N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010; 67(8): 793-802.
91. Rybakowski JK, Permoda-Osip A, Skibinska M, et al. Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved? Hum Psychopharmacol. In press. DOI: 10.1002/hup.2271.
92. Zarate CA, Brutsche NE, Ibrahim L, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry. 2012; 71(11): 939-946.
93. Lu RB, Chen SL, Lee SY, et al. Neuroprotective and neurogenesis agent for treating bipolar II disorder: add-on memantine to mood stabilizer works. Med Hypotheses. 2012; 79(2): 280-283.
94. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry. 2006; 188: 46-50.
95. Keck PE Jr, Mintz J, McElroy SL, et al. Double-blind, randomized, placebo-controlled trials of ethyleicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry. 2006; 60(9): 1020-1022.
96. Miklowitz DJ, Otto MW, Frank E, et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch Gen Psychiatry. 2007; 64(4): 419-426.
97. Colom F, Vieta E, Martinez-Aran A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry. 2003; 60(4): 402-407.
98. Lam DH, Watkins ER, Hayward P, et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry. 2003; 60(2): 145-152.
99. Scott J, Paykel E, Morriss R, et al. Cognitive-behavioural therapy for severe and recurrent bipolar disorders: randomized controlled trial. Br J Psychiatry. 2006; 188: 313-320.
100. Miklowitz DJ, George EL, Richards JA, et al. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry. 2003; 60(9): 904-912.
101. Frank E, Kupfer DJ, Thase ME, et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry. 2005; 62(9): 996-1004.
102. Frank E, Soreca I, Swartz HA, et al. The role of interpersonal and social rhythm therapy in improving occupational functioning in patients with bipolar I disorder. Am J Psychiatry. 2008; 165(12): 1559-1565.
103. Dierckx B, Heijnen WT, van den Broek WW, Birkenha'ger TK. Efficacy of electroconvulsive therapy in bipolar versus unipolar major depression: a metaanalysis. Bipolar Disord. 2012; 14(2): 146-150.
104. Grunhaus L, Schreiber S, Dolberg OT, et al. Response to ECT in major depression: are there differences between unipolar and bipolar depression? Bipolar Disord. 2002; 4(suppl 1): 91-93.
105. Medda P, Perugi G, Zanello S, et al. Response to ECT in bipolar I, bipolar II and unipolar depression. J Affect Disord. 2009; 118(1-3): 55-59.
106. Blanco C, Laje G, Olfson M, et al. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am J Psychiatry. 2002; 159(6): 1005-1010.
107. Koukopoulos A, Albert MJ, Sani G, Koukopoulos AE. Mixed depressive states: nosologic and therapeutic issues. Int Rev Psychiatry. 2005; 17(1): 21-37.
108. Kru' ger S, Young LT, Bra'unig P. Pharmacotherapy of bipolar mixed states. Bipolar Disord. 2005; 7(3): 205-215.
109. Swartz HA, Frank E, Cheng Y. A randomized pilot study of psychotherapy and quetiapine for the acute treatment of bipolar II depression. Bipolar Disord. 2012; 14(2): 211-216.
110. Pacchiarotti I, Valenti' M, Bonnin CM, et al. Factors associated with initial treatment response with antidepressants in bipolar disorder. Eur Neuropsychopharmacol. 2011; 21(5): 362-369.
111. Pacchiarotti I, Valenti' M, Colom F, et al. Differential outcome of bipolar patients receiving antidepressant monotherapy versus combination with an antimanic drug. J Affect Disord. 2011; 129(1-3): 321-326.